Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2025

Impact of ceftazidime-avibactam on mortality in bloodstream infections: a cohort study in patients with acute leukemia.

View Full Paper
Ask AI
Bookmark
Share

Authors

CCCésar Copaja-CorzoSBSusy Bazán-RuizAFAndré Fuentes-Yufra

Discussion

Loading...

Member takes

Overview

Cohort study reveals that ceftazidime-avibactam reduces mortality in acute leukemia patients with bloodstream infections caused by CPE, indicating potential therapeutic benefits.

Key Points

  • Ceftazidime-avibactam significantly reduces the risk of death in patients with bloodstream infections due to CPE.
  • In a cohort of 41 patients, mortality at 30 days was 60.9%, with 48.8% receiving ceftazidime-avibactam.
  • Multivariate analysis indicated an adjusted hazard ratio of 0.29 for those prescribed ceftazidime-avibactam.
  • The findings support the targeted use of ceftazidime-avibactam in immunocompromised patients to improve outcomes.

Cite This Study

Copaja-Corzo et al. (2025) studied this question.

synapsesocial.com/papers/68af3e3ccf1dd9ea359eaf68https://doi.org/10.1177/20499361251362955
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study2025
  2. 2A Comparative Study of Ceftazidime–Avibactam and Meropenem-Based Regimens in the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections in Intensive Care Units2025 · 2 citations
  3. 3Ceftazidime–Avibactam in Critically Ill Patients: A Multicenter Observational Study2025
  4. 4Ceftazidime-Avibactam Plus Aztreonam for the Treatment of Blood Stream Infection Caused by Klebsiella pneumoniae Resistant to All Beta-Lactame/Beta-Lactamase Inhibitor Combinations2025
  5. 5Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections2025